

Richard B Kim

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1508288/richard-b-kim-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

283
papers

25,646
citations

82
h-index

157
g-index

293
ext. papers

27,855
ext. citations

6.7
avg, IF

6.87
L-index

#	Paper	IF	Citations
283	Membrane transporters in drug development. <i>Nature Reviews Drug Discovery</i> , 2010 , 9, 215-36	64.1	2464
282	Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. <i>New England Journal of Medicine</i> , 2020 , 382, 2012-2022	59.2	1616
281	The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. <i>Journal of Clinical Investigation</i> , 1998 , 101, 289-94	15.9	812
280	Identification of functionally variant MDR1 alleles among European Americans and African Americans. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 70, 189-99	6.1	773
279	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 13-33	6.1	659
278	Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. <i>Gastroenterology</i> , 2006 , 130, 1793-806	13.3	492
277	Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. <i>Journal of Biological Chemistry</i> , 2001 , 276, 35669-75	5.4	484
276	Molecular basis of ethnic differences in drug disposition and response. <i>Annual Review of Pharmacology and Toxicology</i> , 2001 , 41, 815-50	17.9	471
275	Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 71, 11-20	6.1	453
274	OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. <i>Drug Metabolism and Disposition</i> , 1999 , 27, 866-71	4	445
273	Genetic determinants of response to warfarin during initial anticoagulation. <i>New England Journal of Medicine</i> , 2008 , 358, 999-1008	59.2	436
272	The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. <i>Nature Medicine</i> , 2003 , 9, 220-4	50.5	389
271	Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. <i>Circulation</i> , 1999 , 99, 552-7	16.7	376
270	Transporters and drug therapy: implications for drug disposition and disease. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 78, 260-77	6.1	366
269	SLC transporters as therapeutic targets: emerging opportunities. <i>Nature Reviews Drug Discovery</i> , 2015 , 14, 543-60	64.1	363
268	Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. <i>Pharmaceutical Research</i> , 1999 , 16, 408-14	4.5	340
267	Intestinal drug transporter expression and the impact of grapefruit juice in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 81, 362-70	6.1	334

266	The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. <i>New England Journal of Medicine</i> , 2001 , 345, 1030-5	59.2	309
265	Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. <i>Journal of Biological Chemistry</i> , 2001 , 276, 39411-8	5.4	301
264	Drugs as P-glycoprotein substrates, inhibitors, and inducers. <i>Drug Metabolism Reviews</i> , 2002 , 34, 47-54	7	297
263	CYP2C9 allelic variants: ethnic distribution and functional significance. <i>Advanced Drug Delivery Reviews</i> , 2002 , 54, 1257-70	18.5	285
262	Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. <i>Journal of Clinical Pharmacology</i> , 2007 , 47, 566-78	2.9	283
261	Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. <i>Drug Metabolism and Disposition</i> , 2000 , 28, 655-60	4	277
260	Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003 , 304, 223-8	4.7	273
259	The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. <i>Pharmacogenetics and Genomics</i> , 2001 , 11, 555-72		269
258	Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. <i>Journal of Biological Chemistry</i> , 2005 , 280, 9610-7	5.4	266
257	Drug transporters in drug efficacy and toxicity. <i>Annual Review of Pharmacology and Toxicology</i> , 2012 , 52, 249-73	17.9	253
256	Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. <i>Molecular Pharmacology</i> , 2001 , 60, 382-7	4.3	248
255	Genetic variability in CYP3A5 and its possible consequences. <i>Pharmacogenomics</i> , 2004 , 5, 243-72	2.6	237
254	Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. <i>Pharmacogenetics and Genomics</i> , 2003 , 13, 595-606		217
253	Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 81, 495-502	6.1	211
252	Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. <i>Journal of Infectious Diseases</i> , 2005 , 192, 1931-42	7	210
251	Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. <i>Molecular Pharmacology</i> , 2002 , 61, 974-81	4.3	192
250	Transporters and renal drug elimination. <i>Annual Review of Pharmacology and Toxicology</i> , 2004 , 44, 137-66	7.9	188
249	Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. <i>Anesthesiology</i> , 2002 , 96, 913-20	4.3	185

248	Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, 41-50	6.1	184
247	Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. <i>Clinical Infectious Diseases</i> , 2006 , 42, 401-7	11.6	181
246	P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. <i>Cancer Research</i> , 1999 , 59, 3944-8	10.1	181
245	Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 56, 359-67	6.1	168
244	Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. <i>Molecular Pharmacology</i> , 2002 , 61, 964-73	4.3	167
243	Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, 170-7	6.1	158
242	Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. <i>European Journal of Clinical Investigation</i> , 2003 , 33 Suppl 2, 1-5	4.6	151
241	Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 539-550		150
240	Human skeletal muscle drug transporters determine local exposure and toxicity of statins. <i>Circulation Research</i> , 2010 , 106, 297-306	15.7	149
239	A 12R-lipoxygenase in human skin: mechanistic evidence, molecular cloning, and expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 6744-9	11.5	149
238	Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 647-56	1.9	148
237	Nuclear receptors and drug disposition gene regulation. <i>Journal of Pharmaceutical Sciences</i> , 2005 , 94, 1169-86	3.9	147
236	Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, 253-63	6.1	146
235	Blood-brain barrier transporters and response to CNS-active drugs. <i>European Journal of Clinical Pharmacology</i> , 2009 , 65, 1063-70	2.8	139
234	Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes. <i>Circulation</i> , 2007 , 115, 432-41	16.7	136
233	Ethnicity-dependent polymorphism in Na ⁺ -taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. <i>Journal of Biological Chemistry</i> , 2004 , 279, 7213-22	5.4	136
232	Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. <i>Clinical Pharmacology and Therapeutics</i> , 1995 , 57, 645-55	6.1	132
231	Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. <i>Canadian Journal of Cardiology</i> , 2013 , 29, S24-33	3.8	128

230	P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. <i>Pharmaceutical Research</i> , 2004 , 21, 1294-302	4.5	126
229	Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. <i>Circulation: Cardiovascular Genetics</i> , 2013 , 6, 400-8		124
228	A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, 366-71	6.1	123
227	Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. <i>Clinical Infectious Diseases</i> , 2006 , 43, 783-6	11.6	122
226	Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 81, 669-78	6.1	118
225	Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. <i>Cancer Research</i> , 2008 , 68, 4983-9	10.1	117
224	Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. <i>Clinical Pharmacology and Therapeutics</i> , 1999 , 66, 224-31	6.1	117
223	Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 890-899	6.1	113
222	Grapefruit juice ingestion significantly reduces talinolol bioavailability. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, 291-301	6.1	112
221	Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 439-48	1.9	109
220	Differential inhibition of rat and human Na ⁺ -dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1) by bosentan: a mechanism for species differences in hepatotoxicity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007 , 321, 1170-8	4.7	108
219	Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 298, F997-F1005	4.3	107
218	Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events. <i>Kidney International</i> , 2016 , 89, 1144-1152	9.9	105
217	Pharmacogenomics of the OATP and OAT families. <i>Pharmacogenomics</i> , 2004 , 5, 273-82	2.6	104
216	Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. <i>Cancer Research</i> , 2008 , 68, 10315-23	10.1	103
215	Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. <i>Molecular Pharmacology</i> , 2008 , 74, 320-9	4.3	103
214	Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. <i>Cancer Research</i> , 2008 , 68, 9338-47	10.1	102
213	Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 1268-74	4	101

212	Hepatic uptake of the novel antifungal agent caspofungin. <i>Drug Metabolism and Disposition</i> , 2005 , 33, 676-82	4	98
211	Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. <i>Oncologist</i> , 2005 , 10, 104-11	5.7	98
210	Impact of genetic variation in OATP transporters to drug disposition and response. <i>Drug Metabolism and Pharmacokinetics</i> , 2013 , 28, 4-18	2.2	93
209	Arg389Gly beta 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. <i>Pharmacogenetics and Genomics</i> , 2001 , 11, 191-7		93
208	Pharmacogenomics of organic anion-transporting polypeptides (OATP). <i>Advanced Drug Delivery Reviews</i> , 2002 , 54, 1343-52	18.5	92
207	Molecular cloning and functional expression of a phorbol ester-inducible 8S-lipoxygenase from mouse skin. <i>Journal of Biological Chemistry</i> , 1997 , 272, 24410-6	5.4	88
206	Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). <i>Drug Metabolism Reviews</i> , 2008 , 40, 317-54	7	86
205	Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. <i>Molecular Pharmacology</i> , 2000 , 57, 24-35	4.3	86
204	Identification of amino acid determinants of the positional specificity of mouse 8S-lipoxygenase and human 15S-lipoxygenase-2. <i>Journal of Biological Chemistry</i> , 2000 , 275, 1287-93	5.4	85
203	Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 318, 1068-75	4.7	84
202	Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. <i>Clinical Infectious Diseases</i> , 2006 , 43, 779-82	11.6	83
201	CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease. <i>Drug Metabolism and Disposition</i> , 2015 , 43, 1484-90	4	78
200	Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, 186-96	6.1	76
199	Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. <i>British Journal of Pharmacology</i> , 2003 , 139, 1111-8	8.6	75
198	MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. <i>Pharmacogenetics and Genomics</i> , 2002 , 12, 425-7		74
197	Identification of amino acids in rat pregnane X receptor that determine species-specific activation. <i>Molecular Pharmacology</i> , 2004 , 65, 36-44	4.3	73
196	Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1999 , 291, 1204-9	4.7	73
195	Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. <i>Blood</i> , 2011 , 118, 3163-71	2.2	72

194	Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 511-6		72
193	Transactivation of rat apical sodium-dependent bile acid transporter and increased bile acid transport by 1alpha,25-dihydroxyvitamin D3 via the vitamin D receptor. <i>Molecular Pharmacology</i> , 2006 , 69, 1913-23	4.3	69
192	Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 317, 1012-8	4.7	67
191	Transporters and xenobiotic disposition. <i>Toxicology</i> , 2002 , 181-182, 291-7	4.4	67
190	Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 103-14	1.9	66
189	The human organic anion transport protein SLC21A6 is not sufficient for bilirubin transport. <i>Journal of Biological Chemistry</i> , 2003 , 278, 20695-9	5.4	64
188	Transporters and drug discovery: why, when, and how. <i>Molecular Pharmaceutics</i> , 2006 , 3, 26-32	5.6	63
187	A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. <i>Drug Metabolism and Disposition</i> , 2008 , 36, 500-7	4	61
186	Human beta2-adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 67, 670-5	6.1	59
185	Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. <i>European Heart Journal</i> , 2012 , 33, 2856-2464a	9.5	58
184	Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). <i>Drug Metabolism and Disposition</i> , 2011 , 39, 558-62	4	57
183	A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. <i>Molecular Endocrinology</i> , 2007 , 21, 1769-80		57
182	Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. <i>Pharmacogenetics and Genomics</i> , 2010 , 20, 45-57	1.9	56
181	In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1996 , 279, 4-11	4.7	56
180	CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 95-105	4.4	55
179	"Inactive" excipients such as Cremophor can affect in vivo drug disposition. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, 394-6	6.1	53
178	Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. <i>PLoS ONE</i> , 2011 , 6, e27808	3.7	52
177	OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. <i>British Journal of Cancer</i> , 2015 , 112, 857-65	8.7	51

176	Liver X receptor and farnesoid X receptor are major transcriptional regulators of OATP1B1. <i>Hepatology</i> , 2010 , 52, 1797-807	11.2	51
175	MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 34, 295-8	3.1	50
174	Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 837-45	1.9	49
173	Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents. <i>Molecular Pharmacology</i> , 2002 , 62, 439-45	4.3	49
172	Environmental and genetic factors affecting transport of imatinib by OATP1A2. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 816-20	6.1	48
171	Beta2-adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo. <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 517-22		48
170	Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling. <i>Drug Metabolism and Disposition</i> , 2015 , 43, 325-34	4	45
169	Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms. <i>Molecular Pharmaceutics</i> , 2009 , 6, 1644-61	5.6	45
168	Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 428-36	3.2	44
167	??1A-Adrenergic receptor polymorphism. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 651-656		44
166	Trimethylamine-N-oxide: a link between the gut microbiome, bile acid metabolism, and atherosclerosis. <i>Current Opinion in Lipidology</i> , 2016 , 27, 148-54	4.4	44
165	Genetic polymorphism of (S)-mephenytoin 4Hydroxylation in populations of African descent. <i>British Journal of Clinical Pharmacology</i> , 1999 , 48, 402-8	3.8	43
164	The anthelmintic agent albendazole does not interact with p-glycoprotein. <i>Drug Metabolism and Disposition</i> , 2002 , 30, 365-9	4	42
163	In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism. <i>Pharmacogenetics and Genomics</i> , 2001 , 11, 809-14		42
162	Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. <i>Cmaj</i> , 2015 , 187, 174-180	3.5	41
161	Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. <i>Biochemical Pharmacology</i> , 2012 , 84, 104-12	6	40
160	Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 3620-30	4	39
159	Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1036-1043	3.8	38

158	Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters. <i>Molecular Pharmaceutics</i> , 2017 , 14, 310-318	5.6	37
157	HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 615-620	6.1	37
156	Toward a personalized medicine approach to the management of inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2014 , 109, 994-1004	0.7	37
155	3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about?. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 381-5	6.1	37
154	Polymorphism screening in the cardiac K ⁺ channel gene KCNA5. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, 138-44	6.1	37
153	St John's wort-associated drug interactions: short-term inhibition and long-term induction?. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 78, 19-24	6.1	37
152	Human MRP3 transporter: identification of the 5' flanking region, genomic organization and alternative splice variants. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1999 , 1415, 369-74	3.8	34
151	The human proton-coupled folate transporter (hPCFT): modulation of intestinal expression and function by drugs. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 298, G248-54	5.1	33
150	and Fluorouracil-Based Chemotherapy: Mini Review and Case Report. <i>Pharmaceutics</i> , 2019 , 11,	6.4	32
149	The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019 , 9,	5.4	31
148	Polymorphisms in beta-adrenergic receptor genes in the acquired long QT syndrome. <i>Journal of Cardiovascular Electrophysiology</i> , 2002 , 13, 252-6	2.7	31
147	Beyond CAR and PXR. <i>Current Drug Metabolism</i> , 2005 , 6, 385-97	3.5	31
146	The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel. <i>Journal of Cardiovascular Pharmacology</i> , 2009 , 54, 63-71	3.1	29
145	Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 61-9	4.4	28
144	Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013 , 112, 164-70	3.1	28
143	Personalized medicine and antiplatelet therapy: ready for prime time?. <i>European Heart Journal</i> , 2009 , 30, 1943-63	9.5	28
142	Modulation by dietary salt of verapamil disposition in humans. <i>Circulation</i> , 1998 , 98, 2702-8	16.7	28
141	Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 994-1003	6.1	27

140	Targeted next generation sequencing as a tool for precision medicine. <i>BMC Medical Genomics</i> , 2019 , 12, 81	3.7	26
139	Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients receiving warfarin. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 1647-54	15.4	26
138	The transfer of pravastatin in the dually perfused human placenta. <i>Placenta</i> , 2013 , 34, 719-21	3.4	26
137	In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 530-42	2.9	25
136	Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2 ^{-/-} mice and intraindividual variability in human subjects. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 1689-97	2.9	25
135	Genetic Determinants of Clozapine-Induced Metabolic Side Effects. <i>Canadian Journal of Psychiatry</i> , 2017 , 62, 138-149	4.8	24
134	Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 69, 317-23	6.1	24
133	Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2). <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 506-15	1.9	23
132	Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis. <i>Toxicology and Applied Pharmacology</i> , 2003 , 186, 119-26	4.6	23
131	Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators. <i>British Journal of Clinical Pharmacology</i> , 1997 , 43, 99-103	3.8	23
130	Fexofenadine and Rosuvastatin Pharmacokinetics in Mice with Targeted Disruption of Organic Anion Transporting Polypeptide 2B1. <i>Drug Metabolism and Disposition</i> , 2019 , 47, 832-842	4	22
129	Transport function and transcriptional regulation of a liver-enriched human organic anion transporting polypeptide 2B1 transcriptional start site variant. <i>Molecular Pharmacology</i> , 2013 , 83, 1218-28	4.3	22
128	HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 356-363	6.1	22
127	Attenuation of bile acid-mediated FXR and PXR activation in patients with Crohn's disease. <i>Scientific Reports</i> , 2020 , 10, 1866	4.9	21
126	Is personalized medicine a dream or a reality?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2015 , 52, 1-11	9.4	20
125	Hepatic organic anion transporting polypeptide transporter and thyroid hormone receptor interplay determines cholesterol and glucose homeostasis. <i>Hepatology</i> , 2011 , 54, 644-54	11.2	20
124	Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. <i>British Journal of Clinical Pharmacology</i> , 2006 , 62, 485-91	3.8	20
123	Transport of the sulfated, amidated bile acid, sulfolithocholyllaurine, into rat hepatocytes is mediated by Oatp1 and Oatp2. <i>Hepatology</i> , 2002 , 35, 1031-40	11.2	20

122	Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22. <i>Breast Cancer Research and Treatment</i> , 2014 , 145, 419-28	4.4	19
121	Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance. <i>Molecular Pharmacology</i> , 2017 , 91, 14-24	4.3	19
120	A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease. <i>Molecular Pharmacology</i> , 2016 , 90, 437-46	4.3	19
119	Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 340-5	6.1	18
118	Organic cation transporter variation and response to smoking cessation therapies. <i>Nicotine and Tobacco Research</i> , 2014 , 16, 1638-46	4.9	18
117	Interaction of three regiospecific amino acid residues is required for OATP1B1 gain of OATP1B3 substrate specificity. <i>Molecular Pharmaceutics</i> , 2012 , 9, 986-95	5.6	18
116	Functional characterization of genetic variants in the apical sodium-dependent bile acid transporter (ASBT; SLC10A2). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26, 1740-8	4	18
115	Alpha 1A-adrenergic receptor polymorphism and vascular response. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 539-45	6.1	18
114	Induction of cytochrome P450 1A by cow milk-based formula: a comparative study between human milk and formula. <i>British Journal of Pharmacology</i> , 2005 , 146, 296-305	8.6	18
113	Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016 , 118, 284-91	3.1	18
112	Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine. <i>Cancer Biotherapy and Radiopharmaceutics</i> , 2010 , 25, 553-7	3.9	17
111	Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity. <i>Pharmacogenetics and Genomics</i> , 1994 , 4, 162-5		17
110	A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. <i>Blood Advances</i> , 2018 , 2, 1935-1945	7.8	17
109	Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 149-156	5.5	16
108	The impact of obesity on the pharmacology of medications used for cardiovascular risk factor control. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 167-76	3.8	16
107	Identification, expression, and functional characterization of full-length and splice variants of murine organic anion transporting polypeptide 1b2. <i>Molecular Pharmaceutics</i> , 2009 , 6, 1790-7	5.6	16
106	Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients. <i>Oral Oncology</i> , 2019 , 89, 72-78	4.4	16
105	Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 367-9	1.9	14

104	Ciprofloxacin and rifampin have opposite effects on levothyroxine absorption. <i>Thyroid</i> , 2013 , 23, 1374-86.2	14
103	Inability to upregulate cytochrome P450 4A and 2C causes salt sensitivity in young Sprague-Dawley rats. <i>American Journal of Hypertension</i> , 2006 , 19, 1174-80	2.3 14
102	Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 49, 294-303	5.1 14
101	Use of transgenic and knockout mouse models to assess solute carrier transporter function. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 612-6	6.1 13
100	Apixaban and Rosuvastatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. <i>Drug Metabolism and Disposition</i> , 2018 , 46, 485-492	4 12
99	Pharmacogenetics of CYP enzymes and drug transporters: remarkable recent advances. <i>Advanced Drug Delivery Reviews</i> , 2002 , 54, 1241-2	18.5 12
98	Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 1477-1491	6.1 12
97	Polymorphism Predisposes to Dopamine Overdose in Parkinson Disease. <i>Frontiers in Neurology</i> , 2018 , 9, 693	4.1 12
96	CYP3A4 Activity is Markedly Lower in Patients with Crohn Disease. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 804-813	4.5 11
95	Statin Safety in Chinese: A Population-Based Study of Older Adults. <i>PLoS ONE</i> , 2016 , 11, e0150990	3.7 11
94	Characterization of the hepatic canalicular membrane transport of a model oligopeptide: ditekiren. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1997 , 281, 297-303	4.7 11
93	CYP2E1 activity is not altered by influenza vaccination. <i>British Journal of Clinical Pharmacology</i> , 1996 , 42, 529-30	3.8 10
92	Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. <i>Annals of Internal Medicine</i> , 2020 , 173, 585-587	8 10
91	Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial Fibrillation. <i>Journal of the American Geriatrics Society</i> , 2019 , 67, 1902-1906	5.6 9
90	Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 1077-1089	6.2 9
89	In Vivo Imaging of Human MDR1 Transcription in the Brain and Spine of MDR1-Luciferase Reporter Mice. <i>Drug Metabolism and Disposition</i> , 2015 , 43, 1646-54	4 9
88	Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?. <i>Journal of Clinical Pharmacology</i> , 2016 , 56 Suppl 7, S40-58	2.9 9
87	Efficacy and plasma drug concentrations with nondaily dosing of rosuvastatin. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 915-9	3.8 9

86	Crohn's Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression. <i>Molecular Pharmaceutics</i> , 2019 , 16, 4059-4064	5.6	8
85	Site-directed mutagenesis studies on a putative fifth iron ligand of mouse 8S-lipoxygenase: retention of catalytic activity on mutation of serine-558 to asparagine, histidine, or alanine. <i>Archives of Biochemistry and Biophysics</i> , 2001 , 386, 136-42	4.1	8
84	Food Effect on Rosuvastatin Disposition and Low-Density Lipoprotein Cholesterol. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 525-533	6.1	8
83	Characterization of OATP1B3 and OATP2B1 transporter expression in the islet of the adult human pancreas. <i>Histochemistry and Cell Biology</i> , 2017 , 148, 345-357	2.4	7
82	Personalized Anticoagulation: Guided Apixaban Dose Adjustment to Compensate for Pharmacokinetic Abnormalities Related to Short-Bowel Syndrome. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 342.e17-342.e19	3.8	7
81	Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNF α biologic for ulcerative colitis: a case report. <i>BMC Cancer</i> , 2016 , 16, 304	4.8	7
80	Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen. <i>Journal of Personalized Medicine</i> , 2017 , 7,	3.6	7
79	Emerging from the shadows: a possible link between sleep apnea and cancer. <i>Journal of Clinical Sleep Medicine</i> , 2014 , 10, 363-4	3.1	7
78	Organic Anion Transporting Polypeptides 75-104		7
77	In Vitro Functional Characterization and in Silico Prediction of Rare Genetic Variation in the Bile Acid and Drug Transporter, Na-Taurocholate Cotransporting Polypeptide (NTCP,). <i>Molecular Pharmaceutics</i> , 2020 , 17, 1170-1181	5.6	6
76	Introduction to Clinical Pharmacology 2017 , 365-388		6
75	Evaluation of herbal products as potential inhibitors of MDR1. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, P79	6.1	6
74	Baclofen has a risk of encephalopathy in older adults receiving dialysis. <i>Kidney International</i> , 2020 , 98, 979-988	9.9	6
73	Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 172, 371-379	4.4	5
72	OCT (SLC22A) and OCTN Family 2013 , 171-208		5
71	Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1. <i>British Journal of Pharmacology</i> , 2010 , 161, 1023-33	8.6	5
70	Transporters and drug disposition. <i>Current Opinion in Drug Discovery & Development</i> , 2000 , 3, 94-101		5
69	Home- vs. Laboratory-Based Management Of OSA: An Economic Review. <i>Current Sleep Medicine Reports</i> , 2016 , 2, 107-113	1.2	4

68	CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy. <i>Breast Cancer Research and Treatment</i> , 2018 , 171, 701-708	4.4	4
67	Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators. <i>British Journal of Clinical Pharmacology</i> , 1997 , 43, 99-103	3.8	4
66	Multiple OATP transporters mediate the cellular uptake of rosuvastatin. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, P64-P64	6.1	4
65	Pharmacogenomics of Drug Transporters 179-213		4
64	Precision Medicine: Lessons Learned From Implementation of a Pharmacogenetics-Based Patient Care Program in a Real-World Setting. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 933-935	6.1	3
63	Incremental lowering of low-density lipoprotein cholesterol with ezetimibe 20 mg vs 10 mg daily in patients receiving concomitant statin therapy. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 1395-9	3.8	3
62	ADME Pharmacogenomics in Drug Development 2013 , 13-37		3
61	MRP4 (ABCC4) 2013 , 365-385		3
60	High affinity uptake by isolated rat hepatocytes of a linear pseudo-hexapeptide, ditekiren. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1997 , 1328, 41-7	3.8	3
59	Genetic variation in the farnesoid X-receptor predicts Crohn's disease severity in female patients. <i>Scientific Reports</i> , 2020 , 10, 11725	4.9	3
58	Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events. <i>Clinical and Translational Science</i> , 2021 , 14, 1338-1348	4.9	3
57	Organic Anion-Transporting Polypeptides 2014 , 43-66		2
56	OATP1B1, OATP1B3, and OATP2B1 2013 , 141-169		2
55	BCRP (ABCG2) 2013 , 311-343		2
54	MRP2 (ABCC2) and MRP3 (ABCC3) 2013 , 345-364		2
53	Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 709-22	5.5	2
52	Pharmacogenetic Advances in Cardiovascular Medicine: Relevance to Personalized Medicine. <i>Current Genetic Medicine Reports</i> , 2013 , 1, 1-14	2.2	2
51	PI-50. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, P20-P20	6.1	2

50	Identification of nonsynonoumous polymorphisms of human organic anion transporting polypeptide-A (OATP-A) associated with altered transport activity. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, P93	6.1	2
49	Duration of Grapefruit Juice Effect on Fexofenadine Interaction. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, P48-P48	6.1	2
48	Drug Transporters 2009 , 45-84		2
47	Regulation of Cytochrome P450 3A4 in Non-Alcoholic Fatty Liver Disease by Fibroblast Growth Factor 21. <i>FASEB Journal</i> , 2013 , 27, lb537	0.9	2
46	Association of Baclofen With Falls and Fractures in Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2021 , 78, 470-473	7.4	2
45	Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2020 , 183, 365-372	4.4	1
44	Introduction to Pharmacogenomics of Drug Transporters 2013 , 1-11		1
43	OATP1A2, OAT1, and OAT3 2013 , 125-139		1
42	P-glycoprotein (MDR1/ABCB1) 2013 , 271-293		1
41	Introduction to Clinical Pharmacology 2009 , 321-338		1
40	PI-32. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, P15-P15	6.1	1
39	PIII-26. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, P65-P65	6.1	1
38	High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor antagonists.. <i>Scientific Reports</i> , 2022 , 12, 1185	4.9	1
37	Near Miss or Standard of Care? Screening for Cancer Patients Receiving Fluorouracil. <i>Current Oncology</i> , 2020 , 28, 94-97	2.8	1
36	Pharmacogenomic-based personalized medicine: Multistakeholder perspectives on implementational drivers and barriers in the Canadian healthcare system. <i>Clinical and Translational Science</i> , 2021 , 14, 2231-2241	4.9	1
35	Mouse NTCP-Mediated Rosuvastatin Uptake In Vitro and in Slc10a1-Deficient Mice. <i>AAPS Journal</i> , 2021 , 23, 17	3.7	1
34	Statin therapy: time for a precision medicine approach?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017 , 2, 187-192	1.6	0
33	Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment. <i>Annals of Internal Medicine</i> , 2021 , 174, 432	8	0

32	Pretreatment HLA-DQA1-HLA-DRB1 Testing for the Prevention of Azathioprine-Induced Pancreatitis in Inflammatory Bowel Disease: A Prospective Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00332	4.2	○
31	Organic Anion Transporting Polypeptide 2B1 (OATP2B1) Genetic Variants: Functional Characterization and Association With Circulating Concentrations of Endogenous Substrates. <i>Frontiers in Pharmacology</i> , 2021 , 12, 713567	5.6	○
30	Association of Sex With Stroke and Bleeding Risk of Apixaban and Rivaroxaban in Elderly Atrial Fibrillation Patients Using Propensity Score Weights.. <i>CJC Open</i> , 2022 , 4, 56-64	2	○
29	Letter: genetic variation in the HLA-DQA1*05 allele predicts tumour necrosis factor- α antagonist immunogenicity - does location matter?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 1055-1056	6.1	○
28	Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 15, 1728-1739	6.9	
27	Letter: predicting azathioprine-associated pancreatitis in IBD-phenotype or genotype? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1044-1045	6.1	
26	Personalized medicine: importance of clinical interpretative skills for real-world patient care. <i>Personalized Medicine</i> , 2014 , 11, 395-408	2.2	
25	Regulatory Perspective on Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 2013 , 39-71		
24	The Pharmacogenomics of Membrane Transporters Project 2013 , 73-108		
23	Emerging New Technology of SNP Typing 2013 , 109-124		
22	MATE (SLC47) Family 2013 , 209-222		
21	BSEP (ABCB11) 2013 , 295-309		
20	Unintended consequences of therapy in the intensive care unit. <i>JAMA Internal Medicine</i> , 2014 , 174, 574-615	6.1,5	
19	Solute Carriers. <i>Cancer Drug Discovery and Development</i> , 2014 , 401-442	0.3	
18	The Relevance of Transporters in Determining Drug Disposition 2006 , 423-459		
17	OII-B-1. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, P5-P5	6.1	
16	Evaluation of ethnicity, gender, and OATP-C genotypes as determinants of pravastatin disposition. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, P66	6.1	
15	A common polymorphism in the adenylyl cyclase type 9 (AC9) gene does not alter vascular responses to isoproterenol. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, P70	6.1	

- 14 Stable and tightly regulated expression of human NA⁺ taurocholate cotransporting polypeptide (NTCP) using a tetracycline-inducible system. *Clinical Pharmacology and Therapeutics*, **2003**, 73, P13-P13 6.1
- 13 Identification of a new beta1-adrenergic receptor variant VAL5ALA more frequent in African-Americans. *Clinical Pharmacology and Therapeutics*, **2003**, 73, P97-P97 6.1
- 12 Grapefruit juice ingestion reduces talinolol serum concentration. *Clinical Pharmacology and Therapeutics*, **2005**, 77, P4-P4 6.1
- 11 Effects of infant formula, cow milk and human milk on drug metabolizing enzymes. *Clinical Pharmacology and Therapeutics*, **2005**, 77, P46-P46 6.1
- 10 Drug efflux transporters and antiviral drug therapy. *Expert Opinion on Therapeutic Targets*, **2000**, 4, 439-446
- 9 Pharmacogenetics of Drug Transporters. *Drugs and the Pharmaceutical Sciences*, **2005**, 109-155
- 8 Human MRP2 polymorphisms and their impact on substrate transport. *FASEB Journal*, **2008**, 22, 1132.4 0.9
- 7 Expression and functional characterization of murine organic anion transporting polypeptide 1b2 (oatp1b2/oatp4/lst-1). *FASEB Journal*, **2008**, 22, 1132.5 0.9
- 6 Genetic and clinical determinants of CYP3A4 activity in patients using 4βhydroxycholesterol as an in vivo probe. *FASEB Journal*, **2013**, 27, 672.3 0.9
- 5 Application of a genomics-guided warfarin dosing nomogram for hospitalized patients. *FASEB Journal*, **2013**, 27, 673.1 0.9
- 4 Letter: immunogenicity of infliximab-ready for routine prediction? AuthorsReply. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 813-814 6.1
- 3 Pharmacokinetics of a once-daily tacrolimus formulation in first nations and caucasian liver transplant recipients. *Transplant International*, **2021**, 34, 2266-2273 3
- 2 ORGANIC ANION TRANSPORTING POLYPEPTIDES OATP **2022**, 79-113
- 1 Correspondence: Failure to Achieve Target Drug Concentrations During Induction and Not HLA-DQA1*05 Carriage is Associated with Anti-Drug Antibody Formation in Patients with Inflammatory Bowel Disease - Is HLADQA1*05 gone before it's here?. *Gastroenterology*, **2022**, 13.3